

**Brasilia, 30 of December of 2002 - 18h20**
**Lipostabil medicine does not possess register in Brazil**

The alert Anvisa to the medical consumers, professionals, proprietors of clinics of aesthetic and pharmacies of manipulation that the Lipostabil medicine (fosfatidilcolina) is not registered in the Anvisa and therefore does not exist authorization for manufacture, importation, distribution, venda and use of this product in the country. The medicine in secrecy comes being used in diverse Brazilian clinics with an indication not proven of reduction of located fats and aesthetic treatment.

IT ALSO SEES:

[Resolution RE nº 30, of 8 of January of 2003](#)

The proper responsible laboratory for the distribution of the Lipostabil medicine in Italy, Germany and other countries, the Aventis Pharma, communicated officially to the Anvisa that not yet commercializes the product in Brazil, reason for which did not request its register. The company also informed that the fosfatidilcolina is a cardiológico medicine indicated for the treatment and Prophylaxis of greasy embolism and that clinical studies do not exist that prove the effectiveness and the security of the product in the dissolution of located fats.

The collateral effect, in the long run, by the use of this product not yet are known. The Aventis Pharma affirms that "due to absence of clinical studies for the aesthetic indication, it does not have as to assure the use of the product, saw application subcutaneous, without it has risks in relation the exaggerated dissolution of fat or the malnutrition of other fabrics beyond the adiposas cells". Moreover, known risks of the fosfatidilcolina exist presented as nauseas, queimação, anorexy, diarréia, depression, profit of weight, arrhythmias, hipotensão and weakness.

The Anvisa comes investigating the improper commercialization and the use and already located two pages in the Internet of companies who irregularly distribute the Lipostabil for all the country. The companies had been litigated and will have that to present defense in the process for the Agency. The Anvisa also requested information on venda of the product for the Italian sanitary authorities and directed craft for the state sanitary monitoring guiding for the actions of fiscalization in establishments of aesthetic, clinical doctors and pharmacies of manipulation.

The Agency informs despite any joined unit of this product for the sanitary inspectors will be collected and the company who will be mattering,

distributing, commercializing or using this product will be litigated and will be able to receive fines that vary of 2 R\$ the a thousand R\$ 1,5 million. In extreme cases, the establishment could be interdicted. Other information or denunciations could be directed to the [Ouvidoria of the Anvisa](#).

These information will be directed for the Federal Advice of Medicine, Nursing, Fisioterapia, Nutrition, Pharmacy, Brazilian Medical Association and Association of Skillful Pharmacies.

The information are of the Agency Health Assessorship of the Anvisa Press  
Email: [imprensa@anvisa.gov.br](mailto:imprensa@anvisa.gov.br)

Endereços Importantes 

[Electronic bulletins](#)

[Public consultations](#)

[Fórum You inform Technician](#)

[Notice](#)



[To come back](#)



[To go up](#)



[To print](#)

Copyright © 2003 - Anvisa